|
PAION AG / Key word(s): Miscellaneous PAION AG: Sale of the business operations 22-Dec-2023 / 16:27 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. PAION AG: Sale of the business operations Aachen (Germany), 22 December 2023 – The Specialty Pharma Company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, PA8) announces that PAION AG and its German subsidiary, PAION Deutschland GmbH, with the approval of the preliminary insolvency administrator of PAION AG and PAION Deutschland GmbH, attorney Dr. Mark Boddenberg, today concluded negotiations with the HumanWell Healthcare Group and entered into an agreement on the sale of the essential business operations of PAION AG and PAION Deutschland GmbH. The proceeds from the sale will go to the insolvency estates of the two companies. PAION AG and PAION GmbH will be wound up as part of the insolvency proceedings; shareholders of PAION AG are not expected to receive any payments. End of Inside Information Information and Explanation of the Issuer to this announcement: PAION contact: Ralf Penner SVP Investor Relations & Corporate Communications PAION AG Heussstrasse 25 52078 Aachen – Germany Phone +49 241 4453-152 E-mail r.penner@paion.com www.paion.com
22-Dec-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Pharma and biotech concerned about the stability of large CROs, survey finds
Share this article In the survey, 80% of respondents no longer favoured the ‘one-stop shop’ model of large CROs. Image credit: Shutterstock / Sai Thaw
February 9, 2024